Navigation Links
LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
Date:3/4/2008

BURLINGTON, Mass., March 4 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of peripheral vascular devices and implants, today announced financial results for Q4 2007 and the year ended December 31, 2007. Q4 2007 revenues were $11.1 million, an increase of 27% over Q4 2006. 2007 revenues were $41.4 million, an increase of 20% over 2006.

Q4 2007 revenues increased 52% in the Company's endovascular and dialysis access category, 17% in its vascular category, and 13% in the general surgery category. For the full year 2007, the Company's endovascular and dialysis access category increased 44%, while the vascular and general surgery categories grew 12% and 2%, respectively. The principal sales drivers in 2007 were the expansion of the sales force, the first year of European distribution of the Endologix stent graft, the weak dollar, and higher average selling prices.

For Q4 2007, the Company reported a gross margin of 73.3% versus 75.3% in the year earlier quarter. This decrease was primarily due to a $105,000 non- cash charge related to OEM inventory included in the December 2007 Biomateriali acquisition. The Company's 2007 gross margin was 74.1% versus 72.9% in 2006. The annual gross margin improvement was primarily driven by price increases and manufacturing cost reductions.

The Company ended 2007 with $22.9 million in cash and cash equivalents. This compares to $25.6 million in cash and cash equivalents at the end of Q3 2007. $2.4 million of this $2.7 million reduction was attributable to the acquisitions executed in Q4 2007.

George W. LeMaitre, Chairman and CEO said, "We had a successful 2007. We grew sales by 20% and posted a record 74.1% gross margin. We also completed four acquisit
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. LeMaitre Vascular, Inc. Schedules Fourth Quarter Results and Conference Call
2. LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
3. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
4. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
5. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
6. LeMaitre Vascular to Start Italian Sales Force
7. Led by Cardiovascular Applications, Double Digit Growth Expected for Catheter Sales
8. Randy Jackson and the American Heart Association Educate Minneapolis Area about the Connection between Type 2 Diabetes and Cardiovascular Disease
9. Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease
10. Curry Ingredient May Cut Cardiovascular Risks
11. Overweight Hispanic children shown to have vascular inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2014)... football players frequently return to the field after an ... American Orthopaedic Society for Sports Medicine,s (AOSSM) Specialty Day. ... factors that affected return to play, including player standing ... shows that about 82% of Division 1 NCAA football ... up to 94% when we focus on players who ...
(Date:3/14/2014)... American Thoracic Society has developed clinical practice guidelines ... sickle cell disease who are at increased risk ... the development of new treatments, many patients with ... to develop pulmonary hypertension, with an estimated prevalence ... Klings, MD, associate professor of medicine at the ...
(Date:3/14/2014)... a devastating experience, and those affected by one often ... many patients, life after a stroke is therefore about ... this is very rarely possible and thus a source ... from University of Copenhagen who has interviewed a number ... Michael Andersen,s PhD thesis was carried out in collaboration ...
(Date:3/14/2014)... (14 March 2014) Leading SAGE medical journal, ... Society (BMS), is expanding its scope and changing its name ... Post Reproductive Health is a MEDLINE indexed, peer ... all those involved in the field of Post Reproductive ... resource for all practitioners and researchers. As the official journal ...
(Date:3/14/2014)... researchers have developed a novel and unique approach ... of blood cancer that often requires repeated chemotherapy ... led by Alexey V. Danilov, MD, PhD, assistant ... Dartmouth and Hematologist-Oncologist at the Norris Cotton Cancer ... cells are found in the laboratory. They were ...
Breaking Medicine News(10 mins):Health News:ATS releases guidelines on the management of pulmonary hypertension of sickle cell disease 2Health News:Stroke patients may benefit from new routines 2Health News:Menopause International re-launching as Post Reproductive Health 2Health News:Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment 2
... July 31 Nevique(TM), a newly,founded skin care ... revolutionary new Omega 3 skin care technology at ... TX on August 5-8, 2008. The,Nevique(TM) skin care ... balm formulas: 1) Ultra Moisturizer, 2) Daily Conditioner, ...
... Cyberonics, Inc. (Nasdaq:,CYBX) today announced that the company will report ... its fiscal year ending April 24,2009 on Thursday, August 21, ... call to discuss those results on the same day at ... Conference Call Instructions, To listen to the conference call ...
... cells to treat fatal disease, researchers say , , THURSDAY, July ... patients with Lou Gehrig,s disease into motor neurons that are ... number of these neurons can now be created and studied ... better understanding of the disease and, one day, lead to ...
... , ... Orlando, FL (Vocus) July 31, 2008 -- ... in its "Hype Cycle for Healthcare Payers, 2008" report. Connextions, a ... retain and manage individual and small group members. , ...
... Announced, ROCHESTER, Mich., July 31 Oakland,University,s ... Robert,Folberg, M.D., as the founding dean of the ... in 2010 with a charter class of,50 students. ... of the,school -- Oakland University William Beaumont School ...
... president & chief operating officer, Medco Health Solutions, Inc.,(NYSE: ... Capital Markets 2008 Focus on,Healthcare Conference in New York ... the Millennium Broadway Hotel will begin at 9:00,a.m. ET. ... to,attend., The presentation may be heard live via ...
Cached Medicine News:Health News:Nevique Skin Care Company Introducing the Revolutionary New Omega 3 Skin Care Technology 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results 2Health News:Scientists Turn Skin Cells Into Motor Neurons in ALS Patients 2Health News:Scientists Turn Skin Cells Into Motor Neurons in ALS Patients 3Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 2Health News:Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications 3Health News:OU, Beaumont Name Dean of New Medical School 2Health News:OU, Beaumont Name Dean of New Medical School 3Health News:Medco to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference 2
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra ... Mr. J. Mark King as its new ... role of Chief Operating Officer, in which he has ... , Mississippi , and Costa ... 20+ years of broad-based operations, sales, engineering and manufacturing ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ... rapid growth of these markets. The ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ... important aspects in today,s growth in the ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Corp. (Nasdaq: BSTC ; the "Company" or ... products, today announced that its Board of Directors has ... 14, 2002 and previously amended June 19, 2003 (the ... for determining "Acquiring Person" status under the Rights Agreement ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) ... signing of an exclusive collaboration and license agreement to ... in Europe and certain other countries in the Middle ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ...
Cached Medicine Technology:Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS 2Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS 3Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS 4Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS 5Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS 6